SLC5A2 and cardiovascular disorder: For example, the cost-effectiveness of sodium-glucose cotransporter 2 (SGLT2) inhibitors for T2D patients with high risk of cardiovascular disease or the cost-effectiveness of SGLT2 inhibitors for T2D patients with chronic kidney disease.